Clinical Trial Update: Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial of dovitinib as first-line treatment for metastatic or locally advanced non-resectable adrenocortical carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenocortical Carcinoma

Drugs mentioned

• Dovitinib (dovitinib)

Snippet

Sponsor: Spanish Oncology Genito-Urinary Group | Conditions: Adrenocortical Carcinoma | Phase 2 | Status: COMPLETED